Drug major Lupin today said it has received approval from the US health regulator to market Desoximetasone Topical spray, used for treatment of plaque psoriasis, in the American market.
Plaque psoriasis is an autoimmune condition that starts well below the skin, causing inflammatory responses that change the life cycle of skin.
These patches or plaques most often appear on the scalp, knees, elbows and lower back.
Psoriasis often develops between the ages of 15 and 35, but can develop at any age.
Plaque psoriasis can cause some complications. The plaques may become infected, especially if they are cracked and bleeding.
Psoriasis affects approximately 7.5 million people in the United States.
It is a generic version of Taro Pharmaceuticals USA Inc.’s Topicort Topical Spray, 0.25 per cent.
The approval has been granted to the product in the size of 30 ml, 50 ml, and 100 ml.
In a BSE filing, Lupin said it has received final approval for the spray, 0.25 per cent, from the United States Food and Drug Administration (USFDA).
As per IQVIA MAT data of January 2018, the product had annual sales of around USD 19.5 million in the US.